10-K: Butterfly Network Files 10-K, Reports on Financial Performance and Strategic Initiatives

Butterfly Network's 10-K filing details its financial results for 2023, strategic shifts, and future growth plans in the medical imaging sector.

Summary

• Butterfly Network, a digital health company, released its 10-K filing, outlining its business, financial condition, and future strategies.
• The company focuses on portable, semiconductor-based ultrasound technology, aiming to democratize healthcare through accessible medical imaging.
• Butterfly's product line includes the Butterfly iQ+ and iQ3 devices, which are handheld ultrasound probes powered by their Ultrasound-on-Chip technology.
• In 2023, Butterfly generated $65.9 million in revenue, compared to $73.4 million in 2022, and incurred net losses of $133.7 million and $168.7 million, respectively.
• The company has reduced its annual cash requirements by approximately $170 million over the past two years and expects its cash to last into 2026.
• Butterfly is expanding its core capabilities in ultrasound education and has launched new revenue streams through its AI marketplace, Butterfly Garden.
• The company is also licensing its Ultrasound-on-Chip technology to non-competitive markets through the Powered by Butterfly program.
• Butterfly is focusing on enterprise sales to healthcare systems, which they believe will generate economies of scale and increase user retention.
• The company is also committed to global health initiatives, distributing devices in low-resource settings and conflict zones.
• Butterfly is exploring patient-focused delivery models, including at-home medical personnel and wearable technology, subject to regulatory approvals.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has made progress in reducing costs and launching new products, revenue has decreased, and the company is still operating at a loss. The future outlook is positive but dependent on successful execution of strategic initiatives and potential capital raises.

Positives

• Butterfly has reduced its annual cash requirements by $170 million, extending its cash runway into 2026.
• The company launched its third-generation device, Butterfly iQ3, which has enhanced features and image quality.
• Butterfly is expanding its revenue streams through its AI marketplace and chip licensing program.
• The company is increasing its focus on enterprise sales, which are expected to generate larger volumes and user retention.
• Butterfly is committed to global health initiatives, providing access to medical imaging in underserved communities.
• The company is exploring future patient-focused delivery models, including at-home care and wearables.

Negatives

• Butterfly's revenue decreased from $73.4 million in 2022 to $65.9 million in 2023.
• The company incurred net losses of $133.7 million in 2023.
• The company relies on single suppliers for some materials and components, which could disrupt production.
• Butterfly faces significant competition from established market participants.
• The company is subject to extensive government regulations, which could restrict its operations and increase costs.
• Butterfly is currently subject to a securities class action lawsuit.

Risks

• Butterfly has a limited operating history and has incurred losses since inception.
• The company may need to raise additional funding, which may not be available on acceptable terms.
• Market acceptance of Butterfly's products and services is crucial for its success.
• Medical device development is costly and involves continual technological change, which may render current products obsolete.
• The company is dependent on the success of its sales and customer acquisition strategies.
• Butterfly relies on limited or sole suppliers for some materials and components.
• The company operates in highly competitive markets, and competition may increase in the future.
• Butterfly is subject to extensive government regulations, which could restrict its operations and increase costs.
• The company is subject to complex and evolving privacy and data protection laws.
• Increased cybersecurity threats pose a risk to Butterfly's systems and data.
• The company may need to obtain licenses from third parties, which may not be available.
• The company is currently subject to a securities class action lawsuit.

Future Outlook

Butterfly intends to develop patient-focused delivery models, including at-home medical personnel and wearable technology, subject to regulatory approvals. The company expects to raise capital before 2026, potentially through grants, debt, or equity securities.

Management Comments

• Butterfly has become a more efficient business while simultaneously investing in long-term growth and innovation.
• The company is focused on staying at the leading edge of technical innovation.
• Butterfly is committed to increasing productivity and efficiency.
• The company is working towards increasingly integrated solutions to maximize value to large healthcare customers.

Industry Context

Butterfly's focus on portable, semiconductor-based ultrasound technology aligns with industry trends towards in-home medical care, affordability, AI integration, and increased access to care. The company's technology is positioned to disrupt the traditional ultrasound market dominated by cart-based devices.

Comparison to Industry Standards

• Traditional cart-based ultrasound devices range from $45,000 to $100,000 per device, while Butterfly's iQ+ is priced at approximately $2,700 and iQ3 at $3,899.
• Incumbent POCUS devices average around $10,000 per device, with additional costs for software and multiple probes, while Butterfly offers a single probe solution.
• Butterfly's semiconductor technology allows its devices to benefit from Moore's Law, unlike traditional piezoelectric crystal-based ultrasound devices.
• Many competitors rely on lead-based piezoelectric crystals, while Butterfly's Ultrasound-on-Chip technology is RoHS-compliant without exemptions.

Legal Proceedings

• The company is currently subject to a securities class action lawsuit.
• The company resolved a patent infringement complaint with Fujifilm during the fourth quarter of 2023.
• The company is also involved in other legal matters for employment-related claims.

Stakeholder Impact

• Shareholders face risks due to the company's losses and potential need for additional capital.
• Employees may be affected by potential future reductions in force.
• Customers may benefit from the company's innovative and affordable ultrasound technology.
• Healthcare providers may benefit from the company's educational offerings and integrated software solutions.
• Patients may benefit from increased access to medical imaging and remote monitoring capabilities.

Next Steps

• Butterfly plans to continue investing in its business to grow revenue.
• The company will focus on expanding its core capabilities in ultrasound education.
• Butterfly will continue to develop and commercialize new products and services.
• The company will work to expand its sales and marketing efforts, particularly in enterprise sales.
• Butterfly will continue to explore patient-focused delivery models, including at-home care and wearables.
• The company will seek additional regulatory authorizations as needed.

Key Dates

Keywords

ultrasound, medical imaging, digital health, semiconductor, point-of-care, handheld, AI, software, healthcare, Butterfly iQ, Butterfly iQ+, Butterfly iQ3, global health, enterprise sales, telemedicine